ClinicalTrials.gg
Not yet recruitingNCT07848737GALILEOUpdated Nov 3, 2026

A Real-World Study of Guselkumab Persistence and Effectiveness in Participants With Crohn's Disease or Ulcerative Colitis

An observational study in Colitis, Ulcerative and Crohn Disease, sponsored by Janssen-Cilag, S.A.. Not yet recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Janssen-Cilag, S.A. (part of Johnson & Johnson) · Observational

How we know

Updated Nov 3, 2026First site in SpainStart date moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Colitis, Ulcerative by Johnson & Johnson — 12 open to participants now, 21 under way, 8 of them phase 3. Colitis, Ulcerative · Johnson & Johnson.

Planned enrollment
8th of 15
200 · median 200
Started
2026
with 6 others
Observational
15 of 43
9 open now
Primary completion
2029-06
later than 14 of 20 live
Registered
42nd of 43
by date

Among the 43 studies in Colitis, Ulcerative by Johnson & Johnson, this one is the 8th largest by planned enrollment of the 15 observational ones that give a count, is one of 7 that started in 2026, is one of 15 observational ones, reaches primary completion later than 14 of the 20 other live ones, and was the 42nd registered.

Colitis, Ulcerative

1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

12 of the 43 studies in Colitis, Ulcerative by Johnson & Johnson are open now, in 12 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Who these studies take

Of the 305 Colitis, Ulcerative studies recruiting now, 135 (44%) set no upper age limit and 134 (44%) stop at 75 or younger; 70 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Colitis, Ulcerative by Johnson & Johnson, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate how long participants with moderate-to-severe Crohn's Disease (CD) and Ulcerative Colitis (UC) continue treatment with guselkumab in a real-world setting. CD and UC are long-term diseases that cause inflammation in intestine (part of digestive system).

03

Conditions studied

  • Colitis, Ulcerative
  • Crohn Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will include participants with confirmed diagnosis of moderate-to-severe Crohn's disease (CD) or Ulcerative colitis (UC) disease.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be eligible for biologic treatment and initiate guselkumab according to the approved indications as described in the current version of the summary of product characteristics (SmPC) of the drug. Decision to prescribe must solely be made by the treating physician. Participant must have been at least 8 weeks under guselkumab treatment before being included in the study, regardless if they are still on guselkumab treatment or not
  • Participant must have a confirmed diagnosis of moderate-to-severe or Crohn's Disease (CD) or Ulcerative Colitis (UC) recorded in their medical records: Harvey-Bradshaw Index (HBI) greater than (>)4 for CD and Partial Mayo Score (pMS)>2 for UC
  • Participant [and/or their legally-acceptable representative where applicable] must sign a participation agreement/ form (ICF) allowing source data verification in accordance with local requirements

Exclusion criteria

Exclusion criteria:

  • to guselkumab per the label
  • It is currently enrolled in an interventional clinical study
  • Has been previously exposed to interleukin (IL)-23 inhibitors, including Tremfya® (guselkumab), Skyrizi® (risankizumab) and Omvoh® (mirikizumab). As an exception, participants with history of ustekinumab exposure, may be included
  • History of more than 4 lines of advanced inflammatory bowel disease (IBD) therapy (biologics and/or small molecules)
  • Is unable to provide the ICF
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Group 1: Moderate-to-Severe Ulcerative Colitis (UC) or Crohn's Disease (CD)

    Participants with confirmed diagnosis of moderate-to-severe UC or CD receiving guselkumab according to clinical practice will be enrolled. Only data available within clinical routine as standard of care will be documented for this study.

06

What researchers measure

Primary outcomes

  1. Persistence of Treatment with Guselkumab

    Persistence of treatment with guselkumab will be measured through time to guselkumab discontinuation defined as the time at which the next infusion should have taken place for a participant after their last scheduled infusion.

    Time frame: Up to 96 weeks

Secondary outcomes

  1. Number of Participants Achieving Clinical Response for Crohn's disease (CD) as Measured by Harvey-Bradshaw Index (HBI)

    Participants reporting effectiveness with treatment of guselkumab will be measured through the HBI for CD. Clinical response for CD is defined as the HBI score less than or equal to (\<=) 4 or a decrease in HBI by greater than or equal to (\>=) 3 from baseline. The HBI consists of a 5-part questionnaire, assessing general wellbeing, abdominal pain (AP), number of liquid stools per day, abdominal mass and complications.

    Time frame: Up to 96 weeks

  2. Number of Participants Achieving Clinical Response for CD as Measured by Patient Reported Outcome (PRO-2)

    Number of participants with clinical response to guselkumab will be assessed using PRO-2, including stool frequency and abdominal pain in CD participants through the patient's electronic (e)-diary.

    Time frame: Up to 96 weeks

  3. Number of Participants Achieving Clinical Response for Ulcerative colitis (UC) as Measured by Partial Mayo Score (PMS)

    Participants reporting effectiveness with treatment of guselkumab will be measured through the PMS for UC. Clinical response for UC is defined as the PMS score \< 4 or \>= 30 percent (%) reduction from baseline. PMS comprises 3 categories: rectal bleeding, stool frequency, and physician assessment.

    Time frame: Up to 96 weeks

  4. Number of Participants Achieving Clinical Response for UC as Measured by PRO-2

    Number of participants achieving clinical response to guselkumab will be assessed using PRO-2, including stool frequency and rectal bleeding in UC participants through the patient's e-diary.

    Time frame: Up to 96 weeks

  5. Characteristics of Participants Receiving Guselkumab Treatment: Age

    Age of participants receiving guselkumab treatment will be reported.

    Time frame: At Week 0

  6. Characteristics of Participants Receiving Guselkumab Treatment: Sex

    Sex of participants receiving guselkumab treatment will be reported.

    Time frame: At Week 0

  7. Characteristics of Participants Receiving Guselkumab Treatment: Previous Inflammatory Bowel Disease (IBD) Medication Use

    Participants with previous IBD medication use will be reported.

    Time frame: At Week 0

  8. Characteristics of Participants Receiving Guselkumab Treatment: Smoking Status and History

    Smoking status and history of participants receiving guselkumab treatment will be reported.

    Time frame: At Week 0

  9. Characteristics of Participants Receiving Guselkumab Treatment: Height

    Height of participants receiving guselkumab treatment will be reported.

    Time frame: At Week 0

  10. Characteristics of Participants Receiving Guselkumab Treatment: Weight

    Weight of participants receiving guselkumab treatment will be reported.

    Time frame: At Weeks 0, 4, 12, 48 and 96

  11. Characteristics of Participants Receiving Guselkumab Treatment: Disease Status

    Disease status of participants receiving guselkumab treatment will be reported.

    Time frame: Up to 96 weeks

  12. Characteristics of Participants Receiving Guselkumab Treatment: Severity at Index

    Disease severity of participants will be reported.

    Time frame: Up To 96 weeks

  13. Characteristics of Participants Receiving Guselkumab Treatment: Age At Diagnosis

    Age at diagnosis of participants receiving guselkumab treatment will be reported.

    Time frame: At Week 0

  14. Characteristics of Participants Receiving Guselkumab Treatment: Disease Duration

    Participants disease duration at study initiation will be reported.

    Time frame: At Week 0

  15. Number of Participants with Comorbid Diagnoses

    Participants with comorbid diagnoses will be reported.

    Time frame: Up to 96 weeks

  16. Number of Participants with History of UC/CD Previous IBD Related Therapy Use and Surgeries

    Participants with history of UC/CD and previous IBD-related therapy use and surgeries will be reported.

    Time frame: At Week 0

  17. Number of Participants Receiving Concomitant IBD Medications

    Participants receiving concomitant IBD medications for UC and CD will be reported.

    Time frame: Up to 96 weeks

  18. Change from Baseline in Health-related Quality of Life (HRQoL) as Measured by Short Inflammatory Bowel Disease Questionnaire (SIBDQ) Scale Score

    The SIBDQ is a 10-item survey measuring HRQoL over the last 2 weeks (frequency of bowel movement, abdominal cramps, fatigue, lack of energy, worry of surgery, fear of no toilet, ability to relax, irritable, impact on leisure, impact on intimacy). The total score ranges from 10 to 70, where high score indicates better QoL.

    Time frame: Baseline (Week 0) up to 96 weeks

  19. Change from Baseline in Satisfaction with Guselkumab Treatment Using Treatment Satisfaction Questionnaire for Medication (TSQM-9) Scale Score

    The TSQM-9 is an abbreviated version of the 14-item TSQM, and is a reliable and valid measure to assess treatment satisfaction in naturalistic study designs, in which there is potential that the administration of the side effects domain of the TSQM would interfere with routine clinical care. It consists of 9 items distributed in the domains: side effects, effectiveness, convenience, and global satisfaction, with scores at each domain ranging from 0 to 100, with higher score indicating higher treatment satisfaction.

    Time frame: Baseline (Week 0) up to 96 weeks

  20. Change in Number of UC/CD Emergency Room Visits

    Change in the number of emergency room visits for treatment of UC/CD will be reported.

    Time frame: Baseline (Week 0) up to 96 weeks

  21. Change in Number of UC/CD-Hospitalizations

    Change in the number of hospitalizations for treatment of UC/CD will be reported.

    Time frame: Baseline (Week 0) up to 96 weeks

  22. Change in Number of UC/CD Surgeries

    Change in the number of surgeries for treatment of UC/CD will be reported.

    Time frame: Baseline (Week 0) up to 96 weeks

  23. Change in C-Reactive Protein (CRP) Levels

    Change in CRP levels since guselkumab initiation will be reported. CRP is a marker of inflammation that will be measured by physicians following routine clinical practice.

    Time frame: At Weeks 0, 4, 12, 48 and 96

  24. Change in Fecal Calprotectin (Fcal) Levels

    Change in Fcal levels since guselkumab initiation will be reported. The Fcal is a marker of inflammation that will be measured by physicians following routine clinical practice.

    Time frame: At Weeks 0, 4, 12, 48 and 96

  25. Number of Participants with Adverse events (AEs)

    An adverse event is any untoward medical occurrence in a participant administered a medicinal product. An AE does not necessarily have a causal relationship with the treatment. An adverse event can be any unfavorable and unintended sign (including an abnormal finding or lack of expected pharmacological action), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to that medicinal product.

    Time frame: Up to 96 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — The data sharing policy of Johnson \& Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.

Data sharing details ↗ · innovativemedicine.jnj.com

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Jun 2029, 31 months later.

Of 83 industry-sponsored observational studies under Colitis, Ulcerative, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 72. This study's planned 31 months is below that.

Counting every sponsor, half of 271 studies reached it within 47 months; a quarter within 29 and three quarters within 90.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, on Nov 3, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2026
First posted
Sep 30, 2026
StartEst.
Nov 15, 2026was Oct 2026
Primary completionEst.
Jun 30, 2029
CompletionEst.
Oct 30, 2029
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added — first site in Spain
Show site
  • Hosp. Clinico Univ. de Santiago · Santiago de Compostela, Spain
Nov 3, 2026
Start date
Oct 30, 2026→Nov 15, 2026
Nov 3, 2026
Registered
First appeared on the registry
Sep 30, 2026
Show all 2 updates
  1. Nov 3, 2026
    1 site added — first site in Spain
    Show site
    • Hosp. Clinico Univ. de Santiago · Santiago de Compostela, Spain
    Start date Oct 30, 2026→Nov 15, 2026
    + 1 other change: verification date
  2. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07848737
Responsible party
Sponsor
First posted
Sep 30, 2026
Start date
Nov 15, 2026 (estimated)
Primary completion
Jun 30, 2029 (estimated)
Completion
Oct 30, 2029 (estimated)
Last update
Nov 3, 2026

Study contacts

Study Contact
Contact
Participate-In-This-Study1@its.jnj.com
844-434-4210
Janssen-Cilag S.A. Clinical Trial
study director · Janssen-Cilag, S.A.

Oversight

Data monitoring committee
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion